Placebo + AZD5069 50mg + AZD5069 80mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
Trial Timeline
Nov 1, 2010 → Mar 1, 2011
NCT ID
NCT01233232About Placebo + AZD5069 50mg + AZD5069 80mg
Placebo + AZD5069 50mg + AZD5069 80mg is a phase 2 stage product being developed by AstraZeneca for Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD). The current trial status is completed. This product is registered under clinical trial identifier NCT01233232. Target conditions include Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01233232 | Phase 2 | Completed |
Competing Products
2 competing products in Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Veliparib | AbbVie | Pre-clinical | 23 |
| fostamatinib + Microgynon® 30 (Oral contraceptive) + Placebo | AstraZeneca | Phase 1 | 33 |